Effect of D-004, a lipid extract from the Cuban royal palm fruit, on in vitro and in vivo effects mediated by α-adrenoceptors in rats

Drugs in R and D

Volumn 6, Issue 5, 2005, Pages 281-289

  Arruzazabala, M L ^a   Mas R ^a   Carbajal, D ^a   Molina, V ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; D 004; LIPID; NORADRENALIN; PLANT EXTRACT; PROSEREN; ROYSTONEA REGIA EXTRACT; SAW PALMETTO EXTRACT; UNCLASSIFIED DRUG; D 004 EXTRACT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARECACEAE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; FRUIT; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; VAS DEFERENS; ANIMAL; CHEMISTRY; CUBA; DISEASE MODEL; METABOLISM; MUSCLE CONTRACTION; ORGAN CULTURE TECHNIQUE; PROSTATE HYPERTROPHY; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; ARECACEAE; CUBA; DISEASE MODELS, ANIMAL; FRUIT; LIPIDS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; ORGAN CULTURE TECHNIQUES; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; VAS DEFERENS;

EID: 33644826635     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506050-00004     Document Type: Article

References (39)

1. Madsen FA, Bruskewitz RC. Benign prostatic hyperplasia pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertens 1995; 4: 455-9
2. Oesterling JE. Benign prostatic hyperplasia: medical and minimal invasive treatment options. N Engl J Med 1995; 332: 99-109
3. Barry MJ, Roehrborn CG. Clinical review: extracts from clinical evidence: benign prostatic hyperplasia. BMJ 2001; 323: 1042-6
4. Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evaluation: recent advances. Curr Opin Urol 2004; 14: 1-6
5. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 Suppl. 1: 2-7
6. Deslypere JP, Young M, Wilson JD, et al. Testosterone and 5 α dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992; 88: 15-22
7. Djavan B, Remzi M, Erne B, et al. The pathophysiology of benign prostatic hyperplasia. Drugs Today (Barc) 2002; 38: 867-76
8. Lepor H, Tang R, Meretyk S, et al. Binding and functional properties of alpha-1 adrenoceptors in different regions of the human prostate. J Urol 1993; 150: 253-6
9. Yamada S, Ashizawa N, Ushijima H, et al. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther 1987; 242: 326-32
10. Wang JM, McKenna KE, McVary KT, et al. Requirement of innervation for the maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991; 44: 1171-6
11. Martínez-Piñeiro L, Dahiya R, Nunes LL, et al. Pelvic plexus denervation in rats causes morphologic and functional changes of the prostate. J Urol 1993; 150: 215-8
12. Roehrborn CG, Schwinn DA. Alpha 1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-35
13. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
14. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A 2002; 41: 412-24
15. Sandhu JS, Te AE. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 2004; 5: 274-9
16. Carruthers SG. Adverse effects of alpha 1 adrenergic blocking drugs. Drug Saf 1994; 11: 12-7
17. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol 2004; 14: 17-20
18. Braekman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res Clin Exp 1994; 55: 776-86
19. Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr Ther Res Clin Exp 1995; 56: 1-22
20. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts on in vitro and in vivo 5 α- reductase inhibition. Prostate 1993; 22: 43-51
21. Bombardelli E, Morazzoni P. Serenoa repens (Bartram) JK Small. Fitoterapia 1997; 68: 99-113
22. Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996; 9: 379-95
23. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
24. Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician 2003; 67: 1281-3
25. Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and non-competitively inhibit human alpha 1 adrenoceptors in vitro. Prostate 1999; 38: 208-15
26. Marks E. Effects of Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000; 163: 1451-6
27. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 1996; 29: 231-40
28. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990; 66: 639-41
29. Gutierrez M, Garcia de Boto MJ, Cantabrana B, et al. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996; 27: 171-6
30. Odenthal KP, Rauwald HW. Lipophilic extract from Sabal serrulata inhibits contractions in smooth muscle tissue. Aktuelle Urol 1996; 27: 152-7
31. Arruzazabala ML, Carbajal D, Mas R, et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exp Clin Res 2004; XXX: 227-33
32. Carbajal D, Arruzazabala ML, Mas R, et al. Effect of D-004, a lipid extract from Cuban Royal Palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: a randomized controlled study. Curr Ther Res Clin Exp 2004; 65: 505-14 2004, 65
33. Michel M, Taguchi K, Schafers RF, et al. α 1-Adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol 1998; 42: 394-8
34. Schafers RF, Poller U, Ponicke K, et al. Adrenergic and muscarinergic blockade and the cardiovascular effects of exogenously administered and endogenously released noradrenaline in humans. Naunyn Schmiedebergs Arch Pharmacol 1996; 335: 239-49
35. Michel MC, Grubbel B, Taguchi K, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16: 21-8
36. Hieble JP, Ruffolo Jr RR. The use of alpha-adrenoreceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 1996; 33: 145-60
37. Kirby RS, Roehrborn CG, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone and in combination, in treatment of benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 267-8
38. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
39. Doggrell SA. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 2004; 5: 1209-11